Focus on development of precision therapeutics could lead to new and more effective treatments in disease areas including cardiovascular and CNS WALTHAM, Mass.–(July 17, 2023, BUSINESS WIRE)–Scipher Medicine today announced that it has entered into a...
First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective...
Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass. (November 10, 2022) – Scipher Medicine announced data validating...
Collaboration Achieves Key Milestones After Preclinical Validation Work, Triggers Milestone Payment to Scipher WALTHAM, Mass. (May 24, 2022) – Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license...
Patients Show Nearly Two-fold Clinical Improvement when Treatment Selection Informed by PrismRA; Predictive Blood Test Could Improve Efficiency in Health Care Spending WALTHAM, Mass. (April 28, 2022) – Scipher Medicine, a precision immunology company matching...
WALTHAM, Mass. (Feb. 28, 2022) – Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced Chief Technology Officer Slava Akmaev, Ph.D., will participate in a virtual panel at the Truist Securities...
